Major players in cancer biomarkers market research that are profiled with Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).
- Agency -.
Access Brochure of Cancer Biomarkers Market spread across 267 Pages, Profiling 16 Companies and supported with 268 Tables and 37 Figures is now available at www.rnrmarketresearch.com/contacts…mple?rname=412680 .
The global cancer biomarkers market is accounted for USD 10.31 Billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 Billion by 2022 during the forecast period. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics.
“The lung cancer segment is expected to register the highest CAGR”
1 Cancer Biomarkers: Market Snapshot
2 Asia Pacific Cancer Biomarkers Market, By Profiling Technology and Application
3 Cancer Biomarkers Market Share, By Cancer Type, 2017 vs 2022
4 Global Market for Cancer Biomarkers: Share, By Biomarker Type, 2015 to 2022
5 Cancer Biomarkers Market, By Region
The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers.
- Agency -.
The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market.
More Information on Cancer Biomakers Market with Complete Overview and Analysis at www.rnrmarketresearch.com/contacts/412680 .
Cancer biomarkers market on the basis of profiling technology is classified into omics technology, imaging technology, immunoassay, bioinformatics, and cytogenetics. Omics technologies segment is expected to account for largest share of global market for cancer biomarkers in 2017.
Demand for advanced omics technologies has increased significantly in recent years mainly due to high-throughput nature of these technologies.
- Manufacturing companies of diagnostics kits and imaging instrument providers
- Biomarkers assay and reagent manufacturers, vendors, and distributors
- Contract research organizations (CROs)
- Companies offering platforms/technologies for cancer diagnosis
- Market research and consulting firms
- Venture capitalists and investors
Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer.
They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids.
Report at www.rnrmarketresearch.com/contacts/?rname=412680 .
Major factors driving growth of cancer markers market are rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, & rising demand for personalized medicine in cancer therapies. High cost of various cancer diagnostic tests, need for high capital investments, poorly suited regulatory & reimbursement systems, & technical issues related to sample collection are restricting growth of this market.
The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future.
Category: Market Research Publishers and RetailersCompany profile: RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
For more information: